Needham Reiterates Buy on Avadel Pharmaceuticals, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a Buy rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and maintained a price target of $22.
September 04, 2024 | 10:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Ami Fadia has reiterated a Buy rating on Avadel Pharmaceuticals and maintained a $22 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $22 price target by a reputable analyst suggests a positive outlook for Avadel Pharmaceuticals. This could lead to increased investor confidence and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100